Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Cut by Fullcircle Wealth LLC

Fullcircle Wealth LLC decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 21.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,153 shares of the biopharmaceutical company’s stock after selling 572 shares during the quarter. Fullcircle Wealth LLC’s holdings in Gilead Sciences were worth $199,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GILD. Nicolet Advisory Services LLC boosted its stake in shares of Gilead Sciences by 2.9% during the 4th quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company’s stock worth $322,000 after acquiring an additional 100 shares in the last quarter. Southland Equity Partners LLC grew its position in Gilead Sciences by 3.6% during the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 110 shares in the last quarter. Berkshire Bank lifted its holdings in shares of Gilead Sciences by 3.4% in the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 111 shares in the last quarter. CFO4Life Group LLC grew its holdings in shares of Gilead Sciences by 2.7% during the fourth quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company’s stock valued at $394,000 after buying an additional 112 shares in the last quarter. Finally, Howe & Rusling Inc. raised its position in Gilead Sciences by 2.5% during the fourth quarter. Howe & Rusling Inc. now owns 4,704 shares of the biopharmaceutical company’s stock valued at $435,000 after buying an additional 115 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total transaction of $266,000.00. Following the transaction, the chief financial officer now owns 168,174 shares in the company, valued at approximately $17,893,713.60. This trade represents a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 160,605 shares of company stock valued at $16,718,136 in the last 90 days. 0.27% of the stock is owned by company insiders.

Analyst Ratings Changes

GILD has been the topic of several research analyst reports. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday, March 27th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Royal Bank of Canada raised their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 12th. Finally, Oppenheimer decreased their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $110.55.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $98.16 on Friday. The stock has a market capitalization of $122.23 billion, a price-to-earnings ratio of 265.30, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The business’s fifty day moving average price is $107.59 and its two-hundred day moving average price is $99.17. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same period in the previous year, the business earned ($1.32) EPS. Gilead Sciences’s revenue was down .3% compared to the same quarter last year. As a group, analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 3.22%. The ex-dividend date is Friday, June 13th. Gilead Sciences’s payout ratio is 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.